<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="407">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    https://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 27, 2015</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01345058</url>
  </required_header>
  <id_info>
    <org_study_id>2010-P-001630</org_study_id>
    <nct_id>NCT01345058</nct_id>
  </id_info>
  <brief_title>Add on Lacosamide Versus High Dose Monotherapy</brief_title>
  <official_title>Open Label Trial of Add on Lacosamide Versus High Dose Monotherapy in Patients With a Seizure Disorder</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Brigham and Women's Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Brigham and Women's Hospital</source>
  <oversight_info>
    <authority>United States: Institutional Review Board</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a study to determine whether a combination of low dose lacosamide and levetiracetam
      is more effective than high dose levetiracetam in patients who have failed low dose
      levetiracetam.
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>March 2011</start_date>
  <completion_date type="Anticipated">December 2014</completion_date>
  <primary_completion_date type="Anticipated">December 2014</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Percentage of patients achieving six month seizure freedom</measure>
    <time_frame>6 months</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of seizure-free months</measure>
    <time_frame>6 months</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to seizure after therapeutic dose is reached</measure>
    <time_frame>6 months</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Retention rate</measure>
    <time_frame>6 months</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of reported side effects</measure>
    <time_frame>6 months</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Epilepsy</condition>
  <arm_group>
    <arm_group_label>Lacosamide add-on</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Lacosamide will be added to low dose levetiracetam</description>
  </arm_group>
  <arm_group>
    <arm_group_label>High dose levetiracetam</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Historical controls will be used as the comparator.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>lacosamide, levetiracetam</intervention_name>
    <description>Lacosamide will be added to levetiracetam: minimum of 200mg/day, to be titrated as follows:
Week 1: 50mg twice a day
Week 2: 100mg twice a day.</description>
    <arm_group_label>Lacosamide add-on</arm_group_label>
    <other_name>Vimpat</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Adults age 18 or older

          2. Determined to have had at least two partial seizures by an epilepsy specialist, or to
             have had a single partial seizure with clinical and/or laboratory evidence of a high
             seizure recurrence risk

          3. Monotherapy on levetiracetam less than or equal to 1500mg/day for at least two weeks

          4. Breakthrough seizure while on stable dose (&gt;5 days) of levetiracetam monotherapy
             regimen, not due to provocative factors (e.g. hypoglycemia, head trauma, missed
             medications)

        Exclusion Criteria:

          1. Clinical suspicion of nonepileptic psychogenic seizures or idiopathic generalized
             epilepsy

          2. Pregnant, child-bearing age not using contraception, or breast feeding

          3. Medical contraindication to adding lacosamide

          4. History of AED polytherapy

          5. Presence of a vagus nerve stimulator

          6. Creatinine clearance of less than 50mL/min

          7. Blood pressure instability: pulse&lt;50 or &gt;100, SBP&lt;50 or &gt;180, clinically significant
             EKG abnormality

          8. History of significant drug rash or anaphylactic reaction with antiepileptic drug

          9. Patients with progressive lesions (e.g. brain tumors)
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jong Woo Lee, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Brigham and Women's Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Brigham and Women's Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2014</verification_date>
  <lastchanged_date>July 20, 2014</lastchanged_date>
  <firstreceived_date>April 28, 2011</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Brigham and Women's Hospital</investigator_affiliation>
    <investigator_full_name>Jong Woo Lee</investigator_full_name>
    <investigator_title>Associate Neurologist</investigator_title>
  </responsible_party>
  <keyword>Epilepsy</keyword>
  <keyword>antiepileptic drug</keyword>
  <keyword>polytherapy</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Etiracetam</mesh_term>
    <mesh_term>Lacosamide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
